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Introduction: In diffuse large B-cell lymphoma, first-line treatment with rituximab, cyclophosphamide, doxorubicin,
vincristine and prednisone; salvage with cisplatin-based regimens for relapsing patients; and autologous stem cell
therapy are standards of care. Treatment approaches are less clear for patients who are refractory or who are not
candidates for autologous stem cell therapy. Options may include palliative regimens or clinical trial enrollment.
One therapy under investigation in diffuse large B-cell lymphoma is lenalidomide, an immunomodulatory agent
with antiangiogenic activity.
Case presentation: We present the case of a 55-year-old Caucasian male patient diagnosed with diffuse large B-cell
lymphoma who had an early relapse after treatment with rituximab, cyclophosphamide, doxorubicin, vincristine, and
prednisone. He then had a subsequent early relapse after cisplatin-based salvage consolidated with autologous
stem cell therapy. The efficacy of gemcitabine-cisplatin-rituximab was limited to five months, followed by
systemic and central nervous system progression. Fourth-line treatment with lenalidomide plus rituximab and
involved-field radiotherapy followed by lenalidomide monotherapy greatly improved this patient’s quality of life
and performance status, allowing over two years of progression-free survival to date (excluding a brief relapse
due to treatment interruption).
Conclusion: A lenalidomide-based regimen was highly effective in this patient with diffuse large B-cell lymphoma.
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Although diffuse large B-cell lymphoma (DLBCL) is an
aggressive lymphoma, immunochemotherapy with ritux-
imab, cyclophosphamide, doxorubicin, vincristine, and
prednisone (R-CHOP) - widely regarded as the standard
of care for first-line patients [1,2] - is effective in more
than 50% of cases [3]. Treatment is not as defined for pa-
tients who are refractory or who relapse following stand-
ard first-line therapy. A number of agents are currently in
development for treating relapsed or refractory DLBCL.
Lenalidomide (Revlimid®, Celgene Corporation, Summit,
New Jersey, USA) is an immunomodulatory agent that is
approved for patients with previously treated multiple
myeloma and for patients with myelodysplastic syndrome
who have the 5q cytogenetic abnormality. Lenalidomide
has both direct tumoricidal and immunomodulatory* Correspondence: wojciech.jurczak@lymphoma.pl
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unless otherwise stated.effects. Direct effects include inhibition of vascular
endothelial growth factor-mediated microvessel forma-
tion, indicating antiangiogenic and antimetastatic activ-
ities [4,5], as well as inhibition of nuclear factor kappa
B to bring about cell cycle arrest and tumor cell death
[6]. Immunomodulatory effects of lenalidomide include
inhibition of pro-inflammatory cytokines such as tumor
necrosis factor α, increased anti-inflammatory cytokines
such as interleukin-10, increased cytotoxicity of natural
killer (NK) cells, and inhibition of regulatory T cells
[7-11]. In addition, lenalidomide is a potent enhancer
of NK cell-mediated and monocyte-mediated tumor
cell antibody-dependent cellular cytotoxicity in non-
Hodgkin’s lymphoma cells treated with the anti-CD20
monoclonal antibody rituximab [12].
Numerous studies of lenalidomide in DLBCL as mono-
therapy or in combination with other agents are ongoing in
first-line patients and relapsed or refractory patients, as well
as in the maintenance setting. In first-line patients with
DLBCL, the combination of lenalidomide with rituximabal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Krawczyk et al. Journal of Medical Case Reports 2014, 8:325 Page 2 of 9
http://www.jmedicalcasereports.com/content/8/1/325plus CHOP (R2-CHOP) has yielded promising results
in phase 1 and 2 studies [13-18]. In relapsed or refrac-
tory DLBCL, data from phase 2 studies of lenalidomide
monotherapy and combination therapy with rituximab
have been presented [19-24], and overall or objective
response rates range from 28% (DLBCL subset) [20] to
35% [21] in this setting. Based on presumptive cell of
origin, there are two primary DLBCL subtypes with dis-
tinct pathophysiology: germinal center B-cell (GCB)
and activated B-cell (ABC)/non-GCB lymphoma. These
are associated with different prognoses. The ABC/non-
GCB subtype has a significantly poorer prognosis than
the GCB subtype, and this correlation is independent of
the International Prognostic Index (IPI) [25,26]. The
benefit of lenalidomide may differ depending on the
subtype of DLBCL [14,27]. In patients with relapsed or
refractory DLBCL treated with salvage lenalidomide, a
higher overall response rate (ORR) has been observed
in patients with the non-GCB subtype compared with
those with the GCB subtype (ORR 52.9% versus 8.7%;
P=0.006) [27]. The benefit of lenalidomide has also
been reported in newly diagnosed patients with non-
GCB subtype DLBCL treated with R2-CHOP. In this
setting, several small (<70 patients), phase 2 studies
have demonstrated that the addition of lenalidomide
improves progression-free survival and overcomes the
negative prognostic impact of the non-GCB subtype on
patient outcome [14,18]. An ongoing phase 2 random-
ized trial (NCT01856192) is comparing progression-Figure 1 Initial histopathologic examination of the gastric biopsy spe
by the diffuse infiltrate composed of large lymphoma cells. Hematoxylin and
lymphoma cells, objective magnification 40×. (c) PAX5 stain positivity in lymp
diffuse large B-cell lymphoma cells on immunohistochemical staining for MIBfree survival in patients with GCB and non-GCB
DLBCL treated with first-line lenalidomide combined
with R-CHOP versus R-CHOP alone [28]. In vitro studies
indicate that the differential effects of lenalidomide on
non-GCB DLBCL cells are dependent on the expression
of interferon regulatory factor 4 and cereblon, an E3 ubi-
quitin ligase complex co-receptor protein [29].
Prognosis is poor for patients with multiply relapsed
or refractory DLBCL, and current treatment guidelines
suggest either autologous stem cell transplant (ASCT)
or treatment within a clinical trial [1,2], underscoring
the dearth of therapeutic options for this population. In
this report, we present the case of a patient with DLBCL
who received lenalidomide plus rituximab after multiple
relapses on other treatments.
Case presentation
Our 55-year-old Caucasian male patient presented with
a two-month history of gastrointestinal symptoms, in-
cluding severe dyspepsia, vomiting, and ‘black stool.’ At
that time, it was not clear whether our patient’s weight
loss (14kg), high fever (>38.5°C), and drenching night
sweats were general symptoms or whether they were the
result of an undiagnosed gastrointestinal tract disorder.
The first histopathological confirmation of lymphoma
came from a gastric biopsy sample (Figure 1) that con-
firmed CD20-positive DLBCL with a high proliferation
fraction (expressed by Ki67 immunohistochemical stain,
which was positive in 90% of the cells). Furthermore, thecimen. (a) Gastric mucosa occupied (the left two-thirds of the image)
eosin (HE) stain, objective magnification 40×. (b) CD20 stain positivity in
homa cells, objective magnification 40×. (d) High proliferative activity of
-1 (Ki67), objective magnification 40×.
Table 1 Treatment regimen for a heavily pretreated
patient with diffuse large B-cell lymphoma
First-line treatment
R-CHOP×8 Rituximab 375mg/m2 (D1)
Cyclophosphamide 750mg/m2 (D1)
Doxorubicin 50mg/m2 (D1)
Vincristine 1.4mg/m2 (D1)a
Prednisone 40mg/m2 (D1 to D5)
Second-line treatment
R-ESHAP×3 Rituximab 375mg/m2 (D1)
Etoposide 40mg/m2/day (D1 to D4)
Methylprednisolone 500mg/m2/day (D1 to D4)b
Cisplatin 25mg/m2/day (D1 to D4)c
Cytarabine 2000mg/m2 (D5)
Z-BEAM Y90-labeled ibritumomab tiuxetan (ZEVALIN)
Carmustine
Etoposide
Cytarabine
Melphalan
Followed by rituximab 375mg/m2,
followed by Y90-labeled ibritumomab
tiuxetan 32mCiu/kg and BEAM
(carmustine, etoposide, cytarabine,
melphalan) -conditioned autologous
stem cell transplant
Third-line treatment
Gemcitabine 1000mg/m2 (D1 to D5)
Cisplatin 80mg/m2 (D1 to D5)
Rituximab 375mg/m2 (D1 to D5)
Prednisone 60mg/m2 (D1 to D5)
Followed by gemcitabine 1,000mg/m2
(every two weeks) and rituximab
375mg/m2 (every four weeks)
Intravenous steroids Dexamethasone 3×8mg
Liposomal cytarabine 50mg (two doses)
Radiotherapy Involved-field RT and prophylactic RT
(26Gy per 10 fractions), then involved-field
RT (8Gy per 1 fraction)
Fourth-line treatment
Lenalidomide 25mg
Rituximab 375mg/m2 (every four weeks)
Palliative RT
Palliative RT
Lenalidomide 10mg/day for 21 days
(every four weeks)
aMaximum 2mg/dose; bmaximum 1,000mg/dose; ccontinuous 24-hour infusion.
D, day; Gy, gray; RT, radiotherapy.
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immunohistochemistry. Our patient was referred from
primary care to a hematologist following analysis of the
gastric biopsy sample. By the time imaging studies were
arranged (one week), generalized lymphadenopathy was
evident, including a cervical lymph node that was nearly
8cm in diameter. Positron emission and computed tom-
ography (PET-CT) imaging demonstrated Ann Arbor
stage IVB with enlarged submandibular, cervical, and me-
diastinal lymph nodes; lung and spleen nodules (172mm);
and gastric infiltration. At the beginning of therapy, our
patient had a high IPI score of 4.
In the first year of therapy (year 1), our patient was
treated with standard R-CHOP chemotherapy (Table 1)
from December of year 1 through May of year 2. A good
clinical response was confirmed on CT imaging per-
formed after cycles four and eight (treatment schema,
Figure 2). Three months after completing first-line ther-
apy, in August of year 2, a complete response (CR) sta-
tus was further confirmed by a PET-CT scan that
revealed cervical lymph nodes (<20mm in the long axis),
with a standard uptake value (SUV) of 2.1, which was
below mediastinal blood pool structure (MBPS) and liver
maximum SUVs (SUVmax) and one 5mm nodule in the
fifth segment of his left lung.
Our patient’s quality of life during first-line treatment
was rather good; symptoms disappeared quickly. For the
most part, he participated in normal daily activities. Treat-
ment was conducted primarily in an outpatient setting.
In December of year 2, CT assessment suggested pos-
sible progression in cervical lymphadenopathy; early re-
lapse was eventually confirmed by histopathology seven
months after completion of the first-line therapy. As a
second line of therapy, our patient received a regimen of
rituximab, etoposide, methylprednisolone, cisplatin, and
cytarabine (R-ESHAP) (Table 1) from March of year 3 to
May of year 3.
A second CR was further consolidated by Z-BEAM-
conditioned (Y90-labeled ibritumomab tiuxetan (Zevalin®,
Spectrum Pharmaceuticals, Henderson, Nevada, USA) com-
bined with the carmustine, etoposide, cytarabine, and
melphalan regimen (BEAM)) ASCT. An initial dose of
rituximab in June of year 3 was followed a week later
by a second rituximab dose plus Y90-labeled ibritumo-
mab tiuxetan and BEAM-conditioned ASCT 11 days
after initiating therapy. Our patient was released from
the hospital in July of year 3, with good hematopoietic
reconstitution and no complications.
At a three-month follow-up visit in October of year 3,
our patient presented with no symptoms or abnormalities
on physical examination. However, a small lesion was de-
tected by PET-CT in his sternum (12mm in diameter,
SUVmax 22.2, MBPS 3.2, liver SUVmax 3.8). A relapse of
his DLBCL with high proliferation fraction was confirmedin material from an urgent partial sternectomy (Figure 3).
Despite this prompt procedure performed by thoracic sur-
geons, the disease progressed in the following months, as
N D
Year 1 Year 7Year 2
J F M A M J J A S O N D J F M A M J J A S O N D J F M A M J J A S O N D J F M A M J J A S O N D J J F MF M A M J J A S O N D
Year 3 Year 4 Year 5 Year 6
First line
R-CHOP ×8
Third line
gemcitabine
+ rituximab
Fourth line
Lenalidomide + rituximab Lenalidomide
Gastric biopsy
Nov Year 1
PET-CT
Aug Year 2
PET-CT
Dec Year 2
1st relapse 4th relapse3rd relapse2nd relapse
CR CR PD includingCNS involvement PR PRPR/SD
PET-CT
Oct Year 3
PET-CT
Mar Year 4
PET-CT
Sep Year 4
PET-CT
Mar Year 5
PET-CT
Aug Year 5
PET-CT
Nov Year 6
PET-CT
Mar Year 7
Lymph node
biopsy
Feb Year 3
Sternum
biopsy
Nov Year 3
IFRT
Apr & Jun
Year 4
IFRT
Apr & Jun
Year 5
Second
line
      R-ESHAP×3
ASCT-
Z-BEAM;
Z + rituximab
Figure 2 Treatment schema. ASCT-Z-BEAM, autologous stem cell transplant conditioned by Z-BEAM (Zevalin® and carmustine, etoposide,
cytarabine, and melphalan); CNS, central nervous system; CR, complete response; IFRT, involved-field radiotherapy; PD, progressive disease; PET-CT,
positron emission tomography-computed tomography; PR: partial response; R-CHOP: rituximab plus cyclophosphamide, doxorubicin, vincristine,
and prednisone; R-ESHAP: rituximab plus etoposide, methylprednisolone, cisplatin, and cytarabine; SD: stable disease; Z: Zevalin®.
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imaging.
Our patient’s quality of life during second-line treatment
and ASCT was poor. There were extensive inpatient pe-
riods and side effects from the intensive chemotherapy.Figure 3 Relapse in the sternum. (a) A bone trabecula in the section of th
(DLBCL) infiltrate. Hematoxylin and eosin (HE) stain, objective magnificatio
magnification 40×. (c) CD79a expression varying in intensity in some cell
expression of the Bcl-2 protein in the DLBCL infiltrate, objective magnificFurthermore, his survival concerns caused great stress and
discomfort.
In December of year 3, our patient started third-line,
gemcitabine-based chemotherapy for debulking (Table 1).
He received gemcitabine with cisplatin, rituximab, ande sternal bone infiltrated and destroyed by diffuse large B-cell lymphoma
n 60×. (b) Strong expression of CD20 in the DLBCL cells, objective
s of the neoplastic infiltrate, objective magnification 40×. (d) Strong
ation 40×.
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weeks and rituximab every four weeks.
Beginning in January of year 4, our patient began to
present unspecified, transient symptoms suggestive of
central nervous system (CNS) involvement: headaches
and signs of VII cranial nerve paralysis. Although this
conclusion could not be definitively diagnosed by lumbar
puncture with cerebrospinal fluid (CSF) cytology and re-
peated imaging studies (CT and magnetic resonance im-
aging), intrathecal liposomal cytarabine was given as
CNS prophylaxis. In April of year 4, our patient pre-
sented with diplopia and right-side ptosis. CT scans
demonstrated a left orbit tumor that infiltrated his
frontal sinus. A neurological examination and CSF cy-
tology were otherwise normal. Our patient received
intravenous steroids and liposomal cytarabine, followed
by involved-field radiotherapy (IFRT) of the orbit in
April of year 4 and prophylactic radiotherapy of the
CNS in May of year 4 (Table 1). The diplopia and ptosis
resolved completely, but he developed bone pain in dif-
ferent locations. This was addressed by palliative IFRT
in April of year 4.
During this period of treatment, our patient’s quality
of life remained poor. He was always either home-bound
or hospitalized and was constantly undergoing medical
procedures, including lumbar puncture. He experienced
pain and the loss of some neurological function, and
continued to be in great stress with survival fears.
Our patient remained on the rituximab therapy
(375mg/m2 every four weeks) initiated during third-line
treatment. In May of year 4, he started fourth-line treat-
ment with lenalidomide in addition to rituximab (Table 1).
In June of year 4, he underwent a second round of pallia-
tive radiotherapy for bone lesions in locations correspond-
ing with bone pain (Figure 4).Figure 4 Radiotherapy sites and dates.In September of year 4, PET-CT indicated a partial re-
sponse; only two bone lesions were found (humeral end
of his right clavicle: 17×23mm, SUVmax 7.1; distal and
proximal ends of his right tibia: SUV 4.9; MBPS 3.5, liver
SUVmax 4.2). Our patient remained free of symptoms
until March of year 5, when PET-CT (Figure 5) revealed
lesions of increased SUV in his pelvis, bilateral femur
and tibia, left ankle, and the humeral end of his right
clavicle; SUVmax of these lesions was up to 4.5, MBPS
2.8. An osteolytic lesion in his T12 vertebra was also de-
scribed. Palliative radiotherapy given in April and June
of year 5 was again successful. His pain resolved, and in
a PET-CT assessment in August of year 5, no new skel-
etal lesions were described. The existing lesions were
not metabolically active (lesions in his right femur, SUV-
max 2.1; left femur, 1.8; bilateral tibias, 1.7 (MBPS 1.9,
liver SUVmax 3.2)). The lenalidomide-plus-rituximab
combination was continued until February of year 6,
when treatment was halted for administrative reasons.
Six weeks after stopping lenalidomide-plus-rituximab
therapy, our patient developed palpable lymphadenop-
athy of 5 to 10mm on his neck, prompting initiation of
lenalidomide monotherapy in March of year 6, which
has continued to date. Due to grade 3 neutropenia as
classified by the Common Terminology Criteria for Ad-
verse Events (version 4.0) [30], the lenalidomide dose
was reduced from 25 to 10mg. Since the start of lenali-
domide monotherapy, our patient has not experienced any
progression, with a negative PET-CT in March of year 7,
and has not experienced any bone pain or lesions.
Hematologic adverse events during lenalidomide-based
treatment were manageable and comprised transient
thrombocytopenia (platelets 39,000 to 80,000/μL, no
treatment required), and leuko- and neutropenia (white
blood cells <1000/μL, polymorphonuclear cells <500;
Figure 5 Positron emission tomography-computed tomography
imaging of bone lesions. (a) Acromial extremity of the right
clavicle, March of year 4. (b) Thoracic vertebra T12, March of year 4.
(c) Right ilium, March of year 5. (d) Distal extremity of the femur
bones, March of year 5.
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support). The cytopenia was exacerbated during the
concomitant palliative radiotherapy. Our patient devel-
oped two infections: sinusitis in March of year 5, which
was treated with amoxicillin, and herpes (varicella zos-
ter virus infection limited to the skin of his left cheek,
with severe neuralgia) from July to October of year 5,
which was treated with acyclovir and analgesics.
During treatment with lenalidomide plus rituximab
and then later on lenalidomide monotherapy, our pa-
tient’s quality of life and performance status remained
surprisingly high (World Health Organization grade 0,
Karnofsky score 100%) and much improved compared
with his quality of life and performance status during
previous therapies. Inpatient hospitalization was not re-
quired, all procedures were performed in a day clinic,
and he returned to full-time work and engaged in phys-
ical activities.
Discussion
DLBCL is the most common aggressive non-Hodgkin’s
lymphoma in adults and accounts for 25% to 35% of
newly diagnosed cases [3,31]. Despite the significant ad-
vances with the addition of rituximab to CHOP chemo-
therapy [32,33], 30% to 40% of patients are refractory or
relapse and eventually succumb. This is particularly frus-
trating in younger patients with a high proliferation frac-
tion. Attempts to improve results in this subgroup have
failed despite early intensification of first-line therapy or
consolidation of the first CR with high-dose chemother-
apy supported by ASCT [34]. Prognosis for patients with
an early relapse after R-CHOP therapy in the first line is
particularly poor [35,36], and much worse than previ-
ously reported by the PARMA trial [37].
Lenalidomide has an acceptable toxicity profile and is
easily manageable and effective in heavily pretreated pa-
tients with high-grade lymphoma [38], based on results
from four multicenter phase 2 trials by Wiernik et al. [19],
Witzig et al. [20], Zinzani et al. [21], and Wang et al. [22].
The first two trials explored the efficacy of lenalidomide
monotherapy in relapsing or refractory DLBCL. Lenalido-
mide (25mg for 21 or 28 days) resulted in ORR up to 37%
[22] and median progression-free survival up to four
months [19,22], with median duration of response from
4.6 to 16 months [20,21]. In the third trial, four cycles of
lenalidomide, rituximab, and dexamethasone induction
were followed by lenalidomide maintenance [21]. Al-
though the ORR was similar (35%), it was long-lasting in
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was manageable and well-tolerated, despite the heavily
pretreated population. The most frequent grade 3 or 4
adverse events were hematologic (neutropenia 30%,
thrombocytopenia 14%, asthenia 5%, and anemia 5%)
[21]. These results are confirmed by case reports from
everyday practice. For example, Rubenstein et al. re-
ported remarkable regression of refractory intraocular
DLBCL during monotherapy with lenalidomide [39].
Lenalidomide is not standard treatment for DLBCL at our
institution, although we had previously observed positive
results among our patients participating in clinical trials of
lenalidomide for refractory non-Hodgkin’s lymphoma.
In our patient, we observed an early relapse after first-
line R-CHOP chemotherapy, indicating a dynamic and
aggressive lymphoma with poor prognosis. Although
radioimmunotherapy (ibritumomab tiuxetan) was added
to a BEAM conditioning regimen supported by ASCT, it
did not overcome disease resistance. Considering the
rapid progression of lymphoma at each relapse, it is very
unlikely that local, palliative radiotherapy would have ef-
fectively cured the disease and prevented distant re-
lapses. Treatment with lenalidomide was considered
under compassionate use after failure of all other treat-
ments available at our institution. The lenalidomide-
rituximab regimen was based on Wiernik and Witzig
protocols [19,20]; however, dexamethasone was omitted
to minimize the risk of osteoporosis and compression
fractures in a patient with lymphoma-infiltrated verte-
brae. This regimen changed the lymphoma dynamics,
allowing more effective radiotherapy and possibly pre-
venting its spread to distant sites, and provided the
longest progression-free survival (eight months after the
R-CHOP chemotherapy and three months after Z-BEAM
ASCT versus 12 months on lenalidomide-rituximab until
treatment break followed by >12 months during lenalido-
mide monotherapy). Our patient’s quality of life was excel-
lent and greatly improved compared with previous therapies,
treatment was outpatient-based, and he returned to
work. Furthermore, this positive clinical response and
improved quality of life were maintained despite treat-
ment interruption and continuation as lenalidomide
monotherapy for over 10 months.Conclusions
We demonstrate that lenalidomide can be efficacious in
DLBCL, and we believe that it should be considered in
relapsed or refractory DLBCL, particularly for heavily
pretreated patients.Consent
Written informed consent was obtained from the patient
for publication of this case report and accompanyingimages. A copy of the written consent is available for re-
view by the Editor-in-Chief of this journal.
Abbreviations
ABC: Activated B-cell; ASCT: Autologous stem cell transplant; BEAM: Carmustine
etoposide, cytarabine, and melphalan; CHOP: Cyclophosphamide doxorubicin,
vincristine, and prednisone; CNS: Central nervous system; CR: Complete
response; CSF: Cerebrospinal fluid; CT: Computed tomography; DLBCL: Diffuse
large B-cell lymphoma; GCB: Germinal center B-cell; HE: Hematoxylin and eosin;
IFRT: Involved-field radiotherapy; IPI: International Prognostic Index;
MBPS: Mediastinal blood pool structures; NK: Natural killer; ORR: Overall
response rate; PD: Progressive disease; PET-CT: Positron emission and computed
tomography; PR: Partial response; R-CHOP: Rituximab plus cyclophosphamide
doxorubicin, vincristine, and prednisone; R-ESHAP: Rituximab plus etoposide
methylprednisolone, cisplatin, and cytarabine; SD: Stable disease; SUV: Standard
uptake value; SUVmax: Maximum standard uptake value; Z: Zevalin.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
KK, WJ, KG, AG, and ABS wrote the paper. All authors read and approved the
final manuscript.
Acknowledgments
We thank Tamara Fink, PhD, of ProEd Communications, Beachwood, Ohio,
USA, for medical editorial assistance with this case report. Support for
medical editorial assistance was provided by Celgene Corporation, Summit,
New Jersey, USA.
Author details
1Department of Hematology, Jagiellonian University, Kopernika 17, Kraków
30-501, Poland. 2Department of Pathology, Jagiellonian University, Kraków,
Poland. 3Department of Tumor Pathology, Center of Oncology, M.
Sklodowska-Curie Memorial Institute, Cracow Branch, Kraków, Poland.
Received: 15 May 2014 Accepted: 21 July 2014
Published: 2 October 2014
References
1. NCCN Clinical Practice Guidelines in Oncology: Non-Hodgkin’s Lymphoma.
Version 1. 2014, 12/20/13. 2014, [http://www.nccn.org/professionals/
physician_gls/pdf/nhl.pdf]
2. Tilly H, Vitolo U, Walewski J, da Silva MG, Shpilberg O, Andre M,
Pfreundschuh M, Dreyling M: Diffuse large B-cell lymphoma (DLBCL):
ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Ann Oncol 2012, 23(Suppl 7):vii78–vii82.
3. Gisselbrecht C, Mounier N: Novel agents for diffuse large B-cell lymphoma.
In 2011 Educational Book. Alexandria, VA: American Society of Clinical
Oncology; 2011:321–325.
4. Lu L, Payvandi F, Wu L, Zhang LH, Hariri RJ, Man HW, Chen RS, Muller GW,
Hughes CC, Stirling DI, Schafer PH, Bartlett JB: The anti-cancer drug
lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory
effects on endothelial cell function in normoxic and hypoxic conditions.
Microvasc Res 2009, 77:78–86.
5. Reddy N, Hernandez-Ilizaliturri FJ, Deeb G, Roth M, Vaughn M, Knight J,
Wallace P, Czuczman MS: Immunomodulatory drugs stimulate natural
killer-cell function, alter cytokine production by dendritic cells, and
inhibit angiogenesis enhancing the anti-tumour activity of rituximab
in vivo. Br J Haematol 2008, 140:36–45.
6. Davis RE, Brown KD, Siebenlist U, Staudt LM: Constitutive nuclear factor
kappaB activity is required for survival of activated B cell-like diffuse
large B cell lymphoma cells. J Exp Med 2001, 194:1861–1874.
7. Corral LG, Haslett PA, Muller GW, Chen R, Wong LM, Ocampo CJ, Patterson
RT, Stirling DI, Kaplan G: Differential cytokine modulation and T cell
activation by two distinct classes of thalidomide analogues that are
potent inhibitors of TNF-alpha. J Immunol 1999, 163:380–386.
8. Galustian C, Meyer B, Labarthe MC, Dredge K, Klaschka D, Henry J, Todryk S,
Chen R, Muller G, Stirling D, Schafer P, Bartlett JB, Dalgleish AG: The anti-
cancer agents lenalidomide and pomalidomide inhibit the proliferation
Krawczyk et al. Journal of Medical Case Reports 2014, 8:325 Page 8 of 9
http://www.jmedicalcasereports.com/content/8/1/325and function of T regulatory cells. Cancer Immunol Immunother 2009,
58:1033–1045.
9. Hayashi T, Hideshima T, Akiyama M, Podar K, Yasui H, Raje N, Kumar S,
Chauhan D, Treon SP, Richardson P, Anderson KC: Molecular mechanisms
whereby immunomodulatory drugs activate natural killer cells: clinical
application. Br J Haematol 2005, 128:192–203.
10. Hsu AK, Quach H, Tai T, Prince HM, Harrison SJ, Trapani JA, Smyth MJ,
Neeson P, Ritchie DS: The immunostimulatory effect of lenalidomide on
NK-cell function is profoundly inhibited by concurrent dexamethasone
therapy. Blood 2011, 117:1605–1613.
11. Schafer PH, Gandhi AK, Loveland MA, Chen RS, Man HW, Schnetkamp PP,
Wolbring G, Govinda S, Corral LG, Payvandi F, Muller GW, Stirling DI:
Enhancement of cytokine production and AP-1 transcriptional activity in
T cells by thalidomide-related immunomodulatory drugs. J Pharmacol
Exp Ther 2003, 305:1222–1232.
12. Wu L, Adams M, Carter T, Chen R, Muller G, Stirling D, Schafer P, Bartlett JB:
Lenalidomide enhances natural killer cell and monocyte-mediated
antibody-dependent cellular cytotoxicity of rituximab-treated CD20+
tumor cells. Clin Cancer Res 2008, 14:4650–4657.
13. Chiappella A, Tucci A, Castellino A, Pavone V, Baldi I, Carella AM, Orsucci L,
Zanni M, Salvi F, Liberati AM, Gaidano G, Bottelli C, Rossini B, Perticone S, De
Masi P, Ladetto M, Ciccone G, Palumbo A, Rossi G, Vitolo U, Fondazione
Italiana Linfomi: Lenalidomide plus cyclophosphamide, doxorubicin,
vincristine, prednisone and rituximab is safe and effective in untreated,
elderly patients with diffuse large B-cell lymphoma: a phase I study by
the Fondazione Italiana Linfomi. Haematologica 2013, 98:1732–1738.
14. Nowakowski G, Reeder CB, Foran JM, Porrata LF, Macon WR, Johnston PB,
Rivera CE, Habermann TM, Inwards DJ, Micallef IN, Johnston PB, Porrata LF,
Ansell SM, Klebig RR, Reeder CB, Witzig TE: Combination of lenalidomide
with RCHOP (R2CHOP) overcomes negative prognostic impact of non-
GCB phenotype in DLBCL—a phase 2 study. Hematol Oncol 2013,
31(Suppl 1):168. abstract 213.
15. Nowakowski GS, LaPlant B, Habermann TM, Rivera CE, Macon WR, Inwards
DJ, Micallef IN, Johnston PB, Porrata LF, Ansell SM, Klebig RR, Reeder CB,
Witzig TE: Lenalidomide can be safely combined with R-CHOP (R2CHOP)
in the initial chemotherapy for aggressive B-cell lymphomas: phase I
study. Leukemia 2011, 25:1877–1881.
16. Nowakowski GS, LaPlant BR, Reeder C, Foran JM, Porrata LF, Macon WR,
Johnston PB, Rivera CE, Habermann TM, Inwards DJ, Micallef IN, Johnston
PB, Porrata LF, Ansell SM, Klebig RR, Reeder CB, Witzig TE: Combination of
lenalidomide with R-CHOP (R2CHOP) is well-tolerated and effective as
initial therapy for aggressive B-cell lymphomas - a phase II study. Blood
2012, 120:ᅟ. abstract 689.
17. Tilly H, Morschhauser F, Salles G, Casasnovas RO, Feugier P, Molina TJ, Jardin
F, Terriou L, Haioun C, Coiffier B: Phase 1b study of lenalidomide in
combination with rituximab-CHOP (R2-CHOP) in patients with B-cell
lymphoma. Leukemia 2013, 27:252–255.
18. Vitolo U, Chiappella A, Franceschetti S, Carella AM, Baldi I, Inghirami G, Spina
M, Pavone V, Ladetto M, Liberati AM, Molinari AL, Zinzani P, Salvi F, Fattori
PP, Zaccaria A, Dreyling M, Botto B, Castellino A, Congiu A, Gaudiano M,
Zanni M, Ciccone G, Gaidano G, Rossi G, Fondazione Italiana Linfomi:
Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse
large B-cell lymphoma: results of the REAL07 open-label, multicentre,
phase 2 trial. Lancet Oncol 2014, 15:730–737.
19. Wiernik PH, Lossos IS, Tuscano JM, Justice G, Vose JM, Cole CE, Lam W,
McBride K, Wride K, Pietronigro D, Takeshita K, Ervin-Haynes A, Zeldis JB,
Habermann TM: Lenalidomide monotherapy in relapsed or refractory
aggressive non-Hodgkin’s lymphoma. J Clin Oncol 2008, 26:4952–4957.
20. Witzig TE, Vose JM, Zinzani PL, Reeder CB, Buckstein R, Polikoff JA,
Bouabdallah R, Haioun C, Tilly H, Guo P, Pietronigro D, Ervin-Haynes AL,
Czuczman MS: An international phase II trial of single-agent lenalidomide
for relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma.
Ann Oncol 2011, 22:1622–1627.
21. Zinzani PL, Pellegrini C, Gandolfi L, Stefoni V, Quirini F, Derenzini E, Broccoli
A, Argnani L, Pileri S, Baccarani M: Combination of lenalidomide and
rituximab in elderly patients with relapsed or refractory diffuse large
B-cell lymphoma: a phase 2 trial. Clin Lymphoma Myeloma Leuk 2011,
11:462–466.
22. Wang M, Fowler N, Wagner-Bartak N, Hagemeister F, Neelapu S, Fanale M,
Younes A, Zhang L, Sun L, Badillo M, Bejarano M, Champlin R, Kwak L, Feng L,
Byrne C, Bell N, Zeldis J, Romaguera J, Fayad L: Oral lenalidomide plus 4 dosesof rituximab induced prolonged remissions in a cohort of patients with
DLBCL and grade 3 follicular lymphoma: a completed phase II
clinical trial. Haematologica 2012, 97(Suppl 1):95. abstract 0237.
23. Wang M, Fowler N, Wagner-Bartak N, Feng L, Romaguera J, Neelapu SS,
Hagemeister F, Fanale M, Oki Y, Pro B, Shah J, Thomas S, Younes A, Hosing C,
Zhang L, Newberry KJ, Desai M, Cheng N, Badillo M, Bejarano M, Chen Y, Young
KH, Champlin R, Kwak L, Fayad L: Oral lenalidomide with rituximab in relapsed
or refractory diffuse large cell, follicular and transformed lymphoma: a phase
II clinical trial. Leukemia 2013, 27:1902–1909.
24. Zinzani PL, Pellegrini C, Derenzini E, Argnani L, Pileri S: Long-term efficacy
of the combination of lenalidomide and rituximab in elderly relapsed/
refractory diffuse large B-cell lymphoma patients. Hematol Oncol 2013,
31:223–224.
25. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC,
Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore T, Hudson J Jr, Lu L,
Lewis DB, Tibshirani R, Sherlock G, Chan WC, Greiner TC, Weisenberger DD,
Armitage JO, Warnke R, Levy R, Wilson W, Grever MR, Byrd JC, Botstein D,
Brown PO, Staudt LM: Distinct types of diffuse large B-cell lymphoma identi-
fied by gene expression profiling. Nature 2000, 403:503–511.
26. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne
RD, Muller-Hermelink HK, Smeland EB, Giltnane JM, Hurt EM, Zhao H, Averett L,
Yang L, Wilson WH, Jaffe ES, Simon R, Klausner RD, Powell J, Duffey PL, Longo
DL, Greiner TC, Weisenberger DD, Sanger WG, Dave BJ, Lynch JC, Vose J,
Armitage JO, Montserrat E, López-Guillermo A: The use of molecular profiling
to predict survival after chemotherapy for diffuse large-B-cell lymphoma.
N Engl J Med 2002, 346:1937–1947.
27. Hernandez-Ilizaliturri FJ, Deeb G, Zinzani PL, Pileri SA, Malik F, Macon WR,
Goy A, Witzig TE, Czuczman MS: Higher response to lenalidomide in
relapsed/refractory diffuse large B-cell lymphoma in nongerminal center
B-cell-like than in germinal center B-cell-like phenotype. Cancer 2011,
117:5058–5066.
28. NCT01856192: Rituximab and Combination Chemotherapy With or
Without Lenalidomide in Treating Patients With Newly Diagnosed Stage
II-IV Diffuse Large B Cell Lymphoma. [http://clinicaltrials.gov/ct2/show/
NCT01856192]
29. Zhang LH, Kosek J, Wang M, Heise C, Schafer PH, Chopra R: Lenalidomide
efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is
dependent upon IRF4 and cereblon expression. Br J Haematol 2013,
160:487–502.
30. US Department of Health and Human Services, National Institutes of Health,
National Cancer Institute. Common Terminology Criteria for Adverse Events,
version 4.0. 2009, [http://evs.nci.nih.gov/ftp1/CTCAE/About.html]
31. Cultrera JL, Dalia SM: Diffuse large B-cell lymphoma: current strategies
and future directions. Cancer Control 2012, 19:204–213.
32. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P,
Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C:
CHOP chemotherapy plus rituximab compared with CHOP alone in
elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002,
346:235–242.
33. Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Ferme C,
Christian B, Lepage E, Tilly H, Morschhauser F, Gaulard P, Salles G, Bosly A,
Gisselbrecht C, Reyes F, Coiffier B: Long-term results of the R-CHOP study
in the treatment of elderly patients with diffuse large B-cell lymphoma:
a study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol
2005, 23:4117–4126.
34. Schmitz N, Nickelsen M, Ziepert M, Haenel M, Borchmann P, Schmidt C,
Viardot A, Bentz M, Peter N, Ehninger G, Doelken G, Ruebe C, Truemper L,
Rosenwald A, Pfreundschuh M, Loeffler M, Glass B, German High-Grade
Lymphoma Study Group (DSHNHL): Conventional chemotherapy (CHOEP-14)
with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for
young, high-risk patients with aggressive B-cell lymphoma: an open-label,
randomised, phase 3 trial (DSHNHL 2002-1). Lancet Oncol 2012, 13:1250–1259.
35. Gisselbrecht C: Is there any role for transplantation in the rituximab era
for diffuse large B-cell lymphoma? Hematology Am Soc Hematol Educ
Program 2012, 2012:410–416.
36. Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M, Bosly A,
Ketterer N, Shpilberg O, Hagberg H, Ma D, Brière J, Moskowitz CH, Schmitz N:
Salvage regimens with autologous transplantation for relapsed large B-cell
lymphoma in the rituximab era. J Clin Oncol 2010, 28:4184–4190.
37. Guglielmi C, Gomez F, Philip T, Hagenbeek A, Martelli M, Sebban C, Milpied N,
Bron D, Cahn JY, Somers R, Sonneveld P, Gisselbrecht C, Van Der Lelie H,
Krawczyk et al. Journal of Medical Case Reports 2014, 8:325 Page 9 of 9
http://www.jmedicalcasereports.com/content/8/1/325Chauvin F: Time to relapse has prognostic value in patients with aggressive
lymphoma enrolled onto the Parma trial. J Clin Oncol 1998, 16:3264–3269.
38. Chiappella A, Vitolo U: Lenalidomide in diffuse large B-cell lymphomas.
Adv Hematol 2012, 2012:498342.
39. Rubenstein JL, Treseler PA, Stewart PJ: Regression of refractory intraocular
large B-cell lymphoma with lenalidomide monotherapy. J Clin Oncol
2011, 29:e595–e597.
doi:10.1186/1752-1947-8-325
Cite this article as: Krawczyk et al.: Lenalidomide in heavily pretreated
refractory diffuse large B-cell lymphoma: a case report. Journal of Medical
Case Reports 2014 8:325.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
